{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"BioBreakthroughs","title":"#27 – Greg Divis, CEO Of Avadel Pharmaceuticals","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/228b5baf\"></iframe>","width":"100%","height":180,"duration":985,"description":"Join us on the latest episode! Our Guest: Greg Divis, CEO at Avadel PharmaceuticalsWhat you'll get out of this episode:Discussing LUMRYZ, a new narcolepsy drug.Insights into the challenges of narcolepsy treatment.Avadel's future plans in healthcare innovation.To learn more about Greg and Avadel Pharmaceuticals:Guest LinkedIn: https://www.linkedin.com/in/greg-divis-a525334/Website: https://www.avadel.com/Company LinkedIn: https://www.linkedin.com/company/avadelpharmaceuticals/Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/BioBreakthroughs is part of the Slice of Healthcare podcast network: LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/","thumbnail_url":"https://img.transistorcdn.com/roxGfgcNItysBs3fg55SsdSx4l_Pbz86Ktm2KMDYkR4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzQwNjg1LzE2ODE5/MzQxODQtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}